Trials / Completed
CompletedNCT01154088
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Mencevax™ ACWY in Healthy Subjects Aged 18-25 Years
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,170 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the observer-blinded study is to determine the immunogenicity and safety of one dose of GlaxoSmithKline (GSK) Biologicals' meningococcal vaccine GSK 134612 compared to one dose of Mencevax™ ACWY in healthy subjects 18-25 years of age. In addition, this study will compare the immunogenicity of two lots of GSK's 134612 vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mencevax ACWY | One dose, Subcutaneous injection |
| BIOLOGICAL | GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612] | One dose, Intramuscular injection |
Timeline
- Start date
- 2010-08-27
- Primary completion
- 2010-12-30
- Completion
- 2010-12-30
- First posted
- 2010-06-30
- Last updated
- 2018-11-26
- Results posted
- 2018-11-26
Locations
3 sites across 3 countries: Panama, Philippines, Thailand
Source: ClinicalTrials.gov record NCT01154088. Inclusion in this directory is not an endorsement.